MedTrace Logo

Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression.

NCT02785562 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2023-10-17

No results posted yet for this study

Summary

Epidemiologic multicenter prospective study in advanced NSCLC patients with PDL1 expression : evaluation of clinical and pathological characteristics of PDL1 high expression patients compared to patients with a weak or no expression of PDL1.

Conditions

Interventions

OTHER

Assessment of PDL1 expression

Intervention : 2 biopsy slides will be analyzed in central laboratory.

Sponsors & Collaborators

  • Groupe Francais De Pneumo-Cancerologie

    lead OTHER

Principal Investigators

  • Christos CHOUAID, Professor · FCPC Vice President

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-21
Primary Completion
2020-04-06
Completion
2020-04-06

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02785562 on ClinicalTrials.gov